- The guidance was updated due to significant advances in clinical trials, particularly in the area of noninvasive testing for MASLD.
- The guideline aims to educate clinicians on the application of noninvasive testing in clinical practice. This includes how to use these tests to risk-stratify patients with MASLD and identify those at risk of progressing to cirrhosis and its complications.
- A key goal of the guideline is to help clinicians identify patients who are most at risk of serious disease progression. These patients require more focused medical attention and intervention.
- The guidance has significant implications for gastroenterology practice, particularly in improving the management and treatment of patients with MASLD.
Previous ArticleUS Insurers Out of Step With IBD Treatment Guidelines (Medscape)
Keep Reading
Add A Comment